Get to know your Medicare plan or explore plans with added benefits and services for you. Individuals and families Get helpful guidance to understand your health plan or find quality coverage for you and your family. Medical providers Join the Aetna network, so together we can give patients acce...
Medicare Medicaid We’re going to explore each option in the next few sections. Medical and Pharmacy Plans There are three different plan levels you can choose from when deciding an individual plan: Bronze, Silver, and Gold. The difference between each plan has to do with the monthly premium...
This Editor explored what happened at Teladoc and the aftermath after some of the dust settled [TTA 9 April]. The Teladoc foundational model as a stand-alone, mostly urgent care service is not growing but shrinking. It doesn’t coordinate care nor does it integrate well into providers. While...
From 2018 to 2023, the Accountable Health Communities model from CMMI reduced expenditures for Medicare and Medicaid beneficiaries, and navigation services were more likely to reach underrepresented groups. More insightshere. More than four in five Medicaid-insured births were free to the patient, vers...
Precertification of alpha 1-proteinase inhibitors (Aralast NP, Glassia, Prolastin-C, and Zemaira) is required of all Aetna participating providers and members in applicable plan designs. For precertification of alpha 1-proteinase inhibitors, call (866) 752-7021 or fax (888) 267-3277. For Stat...
This Clinical Policy Bulletin addresses infliximab for commercial medical plans. For Medicare criteria, seeMedicare Part B Criteria. Note: Requires Precertification: Precertification of infliximab products (Avsola, Inflectra, Remicade, and Renflexis) is required of all Aetna participating providers and mem...
The use of LITT may be a reasonable option in bundled episodes of care for brain cancer and may fit into the Bundled Payment for Care Improvement (BPCI) program being evaluated by Medicare and providers. The authors stated that drawbacks of this analysis included its retrospective nature and ...
This means health care providers and patients can expect the same safety and effectiveness from a biosimilar, just as they would for the reference product (FDA, 2023).Acute Graft Versus Host DiseaseGergis and van Besien (2019) noted that acute graft-versus-host disease (aGVHD) was first ...
Policy Scope of Policy This Clinical Policy Bulletin addresses rituximab for commercial medical plans. For Medicare criteria, seeMedicare Part B Criteria. Note: Requires Precertification: Precertification of rituximab (Rituxan), rituximab-abbs (Truxima), rituximab-arrx (Riabni), rituximab-pvvr (Ruxien...